(Reuters) - Takeda Pharmaceutical Co (4502.T) expects full-year group operating profit to fall 11 percent to about 375 billion yen ($4.43 billion), the Nikkei business daily reported.
Sales are expected to be lower by 4 percent at about 1.41 trillion yen, the paper said.
The company expects net profit to be lower 16 percent at about 250 billion yen, Nikkei said.
The decline in operating profit was contained by lower-than-expected R&D costs, the daily reported.
Full-year R&D expenses were 10-20 billion yen lower than previous estimate despite the company taking a one-time charge on new research facilities and the acquisition of European sales rights for an antipsychotic agent in the January-March quarter, Nikkei added.
Demand in the United States for diabetes medication Actos and multiple myeloma treatment Velcade exceeded expectations while domestic sales for Vectibix, an anticancer agent launched during fiscal 2010, grew, the paper said.
The company is likely to pay a dividend of 180 yen per share, Nikkei reported.
($1 = 84.600 Japanese Yen)
Reporting by Mayuresh Tungare in Bangalore; Editing by Sriraj Kalluvila